Exogene
Phase 3Human T-cells use T-cell receptors to eliminate diseased cells. This natural phenomenon can be harnessed for the development of TCR-based therapies to eradicate solid tumors. However, safe, high-affinity TCRs against cancer targets are rare and hard to identify using traditional wet-lab methods.
Founded
2019
Focus
AI / Machine Learning
About
Human T-cells use T-cell receptors to eliminate diseased cells. This natural phenomenon can be harnessed for the development of TCR-based therapies to eradicate solid tumors. However, safe, high-affinity TCRs against cancer targets are rare and hard to identify using traditional wet-lab methods.
Funding History
1Total raised: $4.2M
Seed$4.2MUndisclosedOct 15, 2021
Company Info
TypePrivate
Founded2019
LocationCambridge, United Kingdom
StagePhase 3
Contact
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile